Effects of the selective metabotropic glutamate agonist LY354740 in a rat model of permanent ischaemia.
The neuroprotective effects of a systemically active, potent, group II selective metabotropic glutamate receptor agonist, LY354740, was assessed in the middle cerebral artery occlusion model of focal ischaemia in rats. LY354740 (0.3, 3.0 or 30.0 mg/kg) was administered subcutaneously (s.c.) 30 min prior to and 3 hours after the induction of ischaemia. Twenty four hours after the ischaemic insult, the brains were processed for the evaluation of infarct volumes. No significant reduction in infarct volumes were observed in treated animals at any of the doses investigated. These data provide no support for the view that group II metabotropic glutamate receptors have a major influence on ischaemic damage in this model.
Lam
A G
AG
Wellcome Surgical Institute and Hugh Fraser Neuroscience Laboratories, University of Glasgow, UK. 9509428/@udcf.gla.ac.uk
Soriano
M A
MA
Monn
J A
JA
Schoepp
D D
DD
Lodge
D
D
McCulloch
J
J
D000818:Animals; D001921:Brain / Q000187:drug effects / Q000473:pathology; D002545:Brain Ischemia / Q000473:pathology*; D001643:Bridged Bicyclo Compounds / Q000494:pharmacology*; D002544:Cerebral Infarction / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D018690:Excitatory Amino Acid Agonists / Q000494:pharmacology*; D008297:Male; D018696:Neuroprotective Agents / Q000494:pharmacology*; D051381:Rats; D011916:Rats, Inbred F344; D018094:Receptors, Metabotropic Glutamate / Q000819:agonists*
D001643:Bridged Bicyclo Compounds; D018690:Excitatory Amino Acid Agonists; D018696:Neuroprotective Agents; D018094:Receptors, Metabotropic Glutamate; C104753:eglumetad